Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma
dc.contributor.author | Urba, Susan G. | en_US |
dc.contributor.author | Orringer, Mark B. | en_US |
dc.contributor.author | Ianettonni, Mark | en_US |
dc.contributor.author | Hayman, James A. | en_US |
dc.contributor.author | Satoru, Hayasaka | en_US |
dc.date.accessioned | 2006-04-19T13:31:24Z | |
dc.date.available | 2006-04-19T13:31:24Z | |
dc.date.issued | 2003-11-15 | en_US |
dc.identifier.citation | Urba, Susan G.; Orringer, Mark B.; Ianettonni, Mark; Hayman, James A.; Satoru, Hayasaka (2003)."Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma." Cancer 98(10): 2177-2183. <http://hdl.handle.net/2027.42/34374> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34374 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14601087&dopt=citation | en_US |
dc.description.abstract | BACKGROUND A Phase II trial was conducted at the University of Michigan to determine the efficacy of a preoperative regimen of concurrent cisplatin, paclitaxel, and radiation for patients with locoregional esophageal carcinoma. METHODS Sixty-nine patients with esophageal carcinoma were treated with cisplatin 75 mg/m 2 on Day 1, paclitaxel 60 mg/m 2 on Days 1, 8, 15, and 22, and radiation 1.5 Gray (Gy) twice per day on Days 1–5, 8–12, and 15–19, for a total dose of 45 Gy. Transhiatal esophagectomy was performed on approximately Day 50. RESULTS The treatment regimen was well tolerated. Only 13% of patients developed Grade 3 or 4 neutropenia and 17% of patients required feeding tubes. Ninety percent of all patients had complete tumor resection at the time of surgery. Nineteen percent of patients achieved a complete histologic response in the resected specimen. The median survival period was 24 months. One-, 2-, and 3-year survival probabilities were 75%, 50%, and 34%, respectively. CONCLUSIONS This cisplatin-based preoperative regimen, which contained paclitaxel rather than 5-fluorouracil, was well tolerated. The survival data compared favorably with other previously reported combinations. This regimen is a reasonable preoperative approach for patients with localized esophageal carcinoma. Cancer 2003. © 2003 American Cancer Society. | en_US |
dc.format.extent | 90988 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan ; Fax: (734) 647-8792 ; University of Michigan Medical Center, 1500 E. Medical Center Drive, 1364 Cancer Center, Ann Arbor, MI 48109 | en_US |
dc.contributor.affiliationum | Department of Thoracic Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Thoracic Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Radiation Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Biostatistics, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan | en_US |
dc.identifier.pmid | 14601087 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34374/1/11759_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/cncr.11759 | en_US |
dc.identifier.source | Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.